Hence, the CD40–CD40L ICP represents an important therapeutic target in transplant therapy (33) and autoimmune diseases (34) as demonstrated by the large number of novel biologics being developed against it including those mentioned in the Introduction, such as letolizumab, dapirolizumab pegol, frexalimab, tegoprubart, TNX-1500, dazodalibep, or iscalimab. The gene discussed is CD40; the disease is autoimmune disease.